Speakers from the world's largest organizations will share their needs and experiences with many world first announcements. Learn of the requirements and case studies from end users and hear all about the latest innovations from companies across the value chain. In total, hear insights from 250 speakers. Register now!
NanoBioSensing. A Powerful New Platform For Real-Time, Continuous, Label-Free Biomarker Monitoring
Santa Clara Convention Center, CA, USA
Conference Room F
15:40 - 16:00
Vista's nanoscale field effect transistors open a whole new vista into label-free, real-time continuous biomarker monitoring, PCR, antibody selection, cell motility, membrane potential, enzyme activity, kinetic and thermodynamic analysis all in a single platform.
Dr. Spencer Farr is a biochemist trained in Bruce Ames lab at UC Berkeley, an NIH Postoctoral Fellow, A Fulbright Scholar at the Institut Jacques Monod in Paris a Faculty member in the Harvard School of Public Health and an Adjunct Professor at MIT. He Co-Founded Vista with Professor Charles Lieber, a Distinguished Professor of Chemistry at Harvard and recognized world leader in nanotechnology. Vista is Dr. Farr's third company and he believes that Vista's NanoBioSensor technology will transform biomarker analysis. He will present several examples of the NanoBioSensor in action.
Vista Therapeutics Inc. was founded to apply advanced nanoscale electronics to address the need for versatile bioassays that can provide results on a continuous, real-time and label-free basis. Vista is a small company located in Santa Fe New Mexico where it has leveraged of the enormous capabilities of Los Alamos and Sandia National labs as well as the Center of Integrated NanoTechnology (CINT). Vista also enjoys close ties with the Harvard and U-Penn nanotechnology institutes. Vista is just now launching its highly versatile NanoBioSensor Platform System.